Figure 9. FOXM1 binds to sites in the SRC promoter and stimulates its expression in breast cancer.

(A) qRT-PCR analysis of Src mRNA levels, normalized to Actb, in mammary glands from MIC/c-Src^+/+ mice treated with vehicle or a FOXM1 inhibitor (NB-55) or from untreated MIC/c-Src^L/L mice. n = 6 per treatment group. ****P < 0.0001, by 1-way ANOVA with Tukey’s post hoc test. (B) qRT-PCR analysis of Src mRNA levels, normalized to Actb, in PyVmT tumors stably expressing the indicated shRNAs. n = 6 per treatment group. ****P < 0.0001, by unpaired, 2-tailed Student’s t test. shCon, control shRNA. (C) Correlation between FOXM1 and SRC expression in a transcriptomic data set from a patient with breast cancer (n = 1,100; Spearman’s rank correlation analysis). TPM, transcripts per million. (D) ChIP and qRT-PCR analysis of FOXM1 binding to the promoters of the indicated genes in PyVmT breast cancer cells. n = 2 cell lines in triplicate. Anti–histone H3 antibody and normal rabbit IgG were used as positive and negative controls, respectively. (E) Schematic diagram illustrating FOXM1 binding to the promoter regions of human and murine SRC.